Most life sciences and biopharma hedge funds are having another rough year. They are either losing money or are up just a few percentage points.
But not Cormorant Asset Management, which has been operating below the radar of many hedge fund watchers.
In the first nine months of this year, the firm headed by Bihua Chen has posted a 20 percent gain in its hedge fund, the Cormorant Global Healthcare Master Fund, according to two people, including an investor.
